Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats

Journal of Psychopharmacology
Ilijana BabicKatrina Weston-Green

Abstract

Antipsychotic drugs (APDs), olanzapine and clozapine, do not effectively address the cognitive symptoms of schizophrenia and can cause serious metabolic side-effects. Liraglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist with anti-obesity and neuroprotective properties. The aim of this study was to examine whether liraglutide prevents weight gain/hyperglycaemia side-effects and cognitive deficits when co-administered from the commencement of olanzapine and clozapine treatment. Rats were administered olanzapine (2 mg/kg, three times daily (t.i.d.)), clozapine (12 mg/kg, t.i.d.), liraglutide (0.2 mg/kg, twice daily (b.i.d.)), olanzapine + liraglutide co-treatment, clozapine + liraglutide co-treatment or vehicle (Control) ( n = 12/group, 6 weeks). Recognition and working memory were examined using Novel Object Recognition (NOR) and T-Maze tests. Body weight, food intake, adiposity, locomotor activity and glucose tolerance were examined. Liraglutide co-treatment prevented olanzapine- and clozapine-induced reductions in the NOR test discrimination ratio ( p < 0.001). Olanzapine, but not clozapine, reduced correct entries in the T-Maze test ( p < 0.05 versus Control) while liraglutide prevented this deficit. Lir...Continue Reading

References

Sep 1, 1993·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·R J BaldessariniB M Cohen
Jun 28, 2000·Biopharmaceutics & Drug Disposition·M AravagiriS R Marder
Aug 17, 2002·The Journal of Pharmacology and Experimental Therapeutics·TracyAnn PerryNigel H Greig
Oct 16, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Nii Addy, Edward D Levin
Dec 31, 2002·Psychoneuroendocrinology·S Kasper, E Resinger
Mar 12, 2003·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·A J Kastin, V Akerstrom
May 22, 2003·Pharmacology, Biochemistry, and Behavior·B PouzetS Velschow
Aug 20, 2003·Nature Medicine·Matthew J DuringColin N Haile
Nov 25, 2003·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Suzanne ArchieJean McNiven
Feb 22, 2005·Schizophrenia Research·Marc PelletierMartin Lepage
Mar 23, 2005·Regulatory Peptides·Philip J Larsen, Jens Juul Holst
Jun 9, 2005·Neurotoxicology and Teratology·Edward D LevinAllison Beatty
Oct 18, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Antonio Ortega-AlvaroJuan A Micó
Dec 15, 2005·Journal of Abnormal Psychology·Junghee Lee, Sohee Park
Dec 17, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Edward D Levin, N Channelle Christopher
Feb 18, 2006·Journal of Clinical and Experimental Neuropsychology·Abraham ReichenbergMichael Davidson
Feb 16, 2007·Biological Psychiatry·James L ReillyJohn A Sweeney
Apr 5, 2007·Nature Protocols·Robert M J Deacon, J Nicholas P Rawlins
Jun 6, 2007·Archives of General Psychiatry·Richard S E KeefeUNKNOWN Neurocognitive Working Group
Oct 12, 2007·Physiological Reviews·Jens Juul Holst
Oct 19, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Shannon Reagan-ShawNihal Ahmad
Jun 27, 2008·Schizophrenia Research·Kirsten LykkegaardLotte Bjerre Knudsen
Jan 31, 2009·Acta Psychiatrica Scandinavica·S M StahlJ M Meyer
Apr 23, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Patrick N McCormickAlan A Wilson
May 11, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Heidi N BoydaAlasdair M Barr
Nov 9, 2010·Behavioural Brain Research·Katrina Weston-GreenChao Deng

❮ Previous
Next ❯

Citations

Jul 19, 2018·Hormone Molecular Biology and Clinical Investigation·Mehmet Akif CamkurtAntonio L Teixeira
May 4, 2018·Journal of Biomedical Science·Katrina Weston-GreenJessica Nealon
Oct 6, 2020·American Journal of Physiology. Endocrinology and Metabolism·Kyle D MedakDavid C Wright
Feb 12, 2021·Journal of Psychopharmacology·Ilijana BabicKatrina Weston-Green
Dec 19, 2020·Frontiers in Psychiatry·Heidi N BoydaAlasdair M Barr
Mar 16, 2021·Frontiers in Endocrinology·Jessica W Y YuenAlasdair M Barr
May 5, 2021·The International Journal of Neuroscience·LongQing ZhangXueBi Tian
May 13, 2021·Acta Pharmacologica Sinica·De-Juan LiChang-Hua Hu
Jul 3, 2021·Expert Opinion on Investigational Drugs·Jonathan FlintoffThomas Hj Burne

❮ Previous
Next ❯

Methods Mentioned

BETA
sedation

Software Mentioned

ARRIVE
Activity Wheel Monitor
SPSS

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here